Suzhou Xinxu Pharmaceutical

Suzhou Xinxu Pharmaceutical, operating globally as Aprinoia Therapeutics, is a clinical-stage biotechnology company specializing in the development of precision diagnostics and therapeutics for neurodegenerative diseases. The company leverages its proprietary platforms to target pathological protein aggregates, specifically Tau and alpha-synuclein, which are central to the pathogenesis of Alzheimer's and Parkinson's diseases. Its lead program, Florzolotau (18F-APN-1607), is a next-generation Tau PET imaging tracer currently in Phase 3 clinical trials for Alzheimer's disease and Progressive Supranuclear Palsy. Beyond diagnostics, the company is advancing a robust pipeline of monoclonal antibodies and small molecule degraders aimed at disease modification. Suzhou Xinxu maintains a significant presence in China, Taiwan, Japan, and the United States, fostering global collaborations for its neuro-focused portfolio.